Search companies

Live

NEXSEN LIMITED (ASX: NXN)

Health care · News and insights

Price unavailable

Latest NXN announcements

Announcement Insights

Nexsen Reworks StrepSure While Advancing RenalSure Toward 2027 FDA Filing

Nexsen’s diagnostics pipeline is advancing on separate tracks: StrepSure’s clinical study was suspended after the company identified changes to improve the test, while RenalSure is progressing toward a targeted mid-2027 US FDA submission, subject to development and clinical validation. In November, Nexsen secured ISO 13485 certification intended to support StrepSure regulatory submissions and commercial supply, and began a feasibility study for a complementary kidney-test cartridge with GENSPEED. The company also added clinical and hospital expertise to its advisory board to support development and validation.

Updated 16 Nov 2026, 09:50 AM Sydney time
Share
SourcesNexsen Appointments to Advisory BoardResults of MeetingNexsen advances kidney diagnostics programISO 13485 Certification brings StrepSure closer to marketCo Secretary Appoint/Resign and Change of Registered AddressQuarterly Report - Q1 FY27
Comments

Nexsen Names Gleneagles Hospital CEO to Chair Advisory Board

2026-11-16 · Health care

NXN: $0.150 -3.23% · MC: $32M

Nexsen has appointed Gleneagles Hospital Hong Kong CEO Kenneth Tsang as Advisory Board chair and intensive-care kidney injury expert Professor Kwok-ming Ho as a member. The company says the appointments are intended to support development and clinical validation of its diagnostics, including RenalSure, which is targeting a US FDA submission in mid-2027.

Updated 2026-11-16 09:37
Share
SourcesNexsen Appointments to Advisory Board
Comments

Nexsen Targets Mid-2027 FDA Filing As Kidney Test Program Expands

2026-11-06 · Health care

NXN: $0.165 +3.13% · MC: $32M

Nexsen says its RenalSure kidney test is progressing towards a targeted US FDA submission in mid-2027, subject to development and clinical validation. It has also begun a feasibility study with GENSPEED on a complementary cartridge-based test, intended to broaden its offering for hospital monitoring; the company cites a global acute kidney injury diagnostics market forecast to grow from about US$1 billion to about US$2 billion by 2033.

Updated 2026-11-06 09:52
Share
SourcesNexsen advances kidney diagnostics program
Comments

Nexsen Secures Medical-Device Quality Certification, Advancing StrepSure Toward Market

2026-11-02 · Health care

NXN: $0.160 +0.00% · MC: $32M

Nexsen Limited (ASX: NXN) has secured ISO 13485 certification covering StrepSure’s design, development and manufacture, establishing a certified quality system intended to support regulatory submissions and commercial supply. The certification advances the product toward an Asia-Pacific launch and FDA submission, and the company says the quality framework can also support other diagnostics in its pipeline. Nexsen also appointed Amanda Burgess as company secretary and changed its registered office.

Updated 2026-11-02 17:16
Share
SourcesISO 13485 Certification brings StrepSure closer to marketCo Secretary Appoint/Resign and Change of Registered Address
Comments

Nexsen proposes FlashDx joint venture as it broadens diagnostics pipeline

2026-10-28 · Health care

NXN: $0.160 -3.03% · MC: $32M

Nexsen signed a non-binding term sheet for a proposed 50:50 joint venture with FlashDx to develop and commercialise an enhanced GBS test, complementing its StrepSure program for different clinical settings. The company says it has identified changes intended to improve StrepSure ahead of a US regulatory submission, after suspending enrolment in its clinical study and ending assessment of the test in its current form; it reported no adverse safety signal or event. Nexsen also established a Hong Kong research base and added traumatic brain injury and neonatal sepsis programs to its diagnostics pipeline.

Updated 2026-10-28 11:56
Share
SourcesQuarterly Report - Q1 FY27
Comments